Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma
CONCLUSIONS: The addition of daratumumab to lenalidomide and dexamethasone significantly lengthened progression-free survival among patients with relapsed or refractory multiple myeloma. Daratumumab was associated with infusion-related reactions and a higher rate of neutropenia than the control therapy. (Funded by Janssen Research and Development; POLLUX ClinicalTrials.gov number, NCT02076009.)
N Engl J Med
In The News
American Society of Hematology 2016 Annual Meeting
Session 731. Clinical Autologous Transplantation: Results: Clinical Autologous Transplantation in Myeloma I
American Society of Hematology 2016 Annual Meeting
Session 653. Myeloma: Therapy, excluding Transplantation: IMiD/Proteasome Inhibitor Combinations and Maintenance Therapy
American Society of Hematology 2016 Annual Meeting
Abstract 1143: Lenalidomide Is a Highly Effective Maintenance Therapy in Myeloma Patients of All Ages; Results of the Phase III Myeloma XI Study
American Society of Hematology 2016 Annual Meeting
Abstract 673: Intensification Therapy with Bortezomib-Melphalan-Prednisone Versus Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma: An Intergroup, Multicenter, Phase III Study of the European Myeloma Network (EMN02/HO95 MM Trial)
In The Literature
Bone Marrow Transplant